XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 215,432,713 $ 22,196,097
Short-term investments 156,231,102 67,338,017
Accounts receivable 3,513,159 700,073
Accounts receivable from affiliated entities 482,373 1,332,044
Prepaid expenses and other current assets 4,591,966 1,584,598
Prepaid expenses and other current assets from affiliated entities 1,811,140 1,050,140
Total current assets 382,062,453 94,200,969
Fixed assets, net 11,323,531 12,773,017
Investment in affiliated entities 17,327,569 6,315,356
Investment in Geneos 2,717,241 0
Intangible assets, net 3,420,311 3,693,851
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 13,265,144 13,783,009
Other assets 2,555,782 2,672,024
Total assets 443,185,402 143,951,597
Current liabilities:    
Accounts payable and accrued expenses 17,216,875 18,237,258
Accounts payable and accrued expenses due to affiliated entities 511,953 729,729
Accrued clinical trial expenses 6,870,450 4,049,727
Deferred revenue 14,853 92,353
Deferred revenue from affiliated entities 94,275 31,775
Operating lease liability 2,200,459 2,074,842
Grant funding liability 10,330,235 6,065,212
Grant funding liability from affiliated entities 742,875 708,425
Total current liabilities 37,981,975 31,989,321
Deferred revenue, net of current portion 86,641 101,567
Derivative liability 119,796,000 8,819,023
Operating lease liability, net of current portion 19,261,354 20,409,922
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 37,500 135,000
Other liabilities 66,629 36,943
Total liabilities 256,824,933 138,546,739
Stockholders’ equity:    
Preferred stock 0 0
Common stock 158,756 101,361
Additional paid-in capital 1,087,745,242 742,646,785
Accumulated deficit (901,029,768) (739,785,655)
Accumulated other comprehensive income (loss) (610,030) 472,608
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 186,264,200 3,435,099
Non-controlling interest 96,269 1,969,759
Total stockholders’ equity 186,360,469 5,404,858
Total liabilities and stockholders’ equity 443,185,402 143,951,597
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 65,844,260 64,180,325
Convertible Bonds    
Current liabilities:    
Convertible debt $ 13,718,528 $ 12,842,592